Consensus on Biological Agents in Treating Patients With Inflammatory Bowel Disease / 胃肠病学
Chinese Journal of Gastroenterology
; (12): 601-614, 2022.
Article
in Zh
| WPRIM
| ID: wpr-1016078
Responsible library:
WPRO
ABSTRACT
Biological agents have been increasingly used in the treatment of inflammatory bowel disease (IBD) in China. As the types of biologics and approved indications gradually increase, the rationale, effective and safe use of various biological agents pose new challenges to clinicians. In order to standardize the use of biological agents to treat IBD, Inflammatory Bowel Disease Quality Control Center and Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology organized experts to formulate this guidance on indications, contraindications, effectiveness, screening and preventing opportunistic infections, methods of application, response monitoring, issues for special population and safety for use of biological agents. This consensus is expected to facilitate the standard use of biologics in patients with IBD in China.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Gastroenterology
Year:
2022
Type:
Article